{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:50:28Z","timestamp":1785426628367,"version":"3.56.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00702-024-02805-y","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T14:29:43Z","timestamp":1721917783000},"page":"1321-1328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapy with botulinum neurotoxin for Parkinson\u2019s disease"],"prefix":"10.1007","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-3297","authenticated-orcid":false,"given":"Wolfgang H.","family":"Jost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Berberovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"2805_CR1","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/mds.870120524","volume":"12","author":"A Albanese","year":"1997","unstructured":"Albanese A, Maria G, Bentivoglio AR et al (1997) Severe constipation in Parkinson\u2019s disease relieved by botulinum toxin. Mov Disord 12:764\u2013766. https:\/\/doi.org\/10.1002\/mds.870120524","journal-title":"Mov Disord"},{"key":"2805_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/jnnp.2009.174698","volume":"81","author":"E Alfonsi","year":"2010","unstructured":"Alfonsi E, Merlo IM, Ponzio M et al (2010) An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment. J Neurol Neurosurg Psychiatry 81:54\u201360. https:\/\/doi.org\/10.1136\/jnnp.2009.174698","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2805_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fphar.2017.00080","volume":"8","author":"E Alfonsi","year":"2017","unstructured":"Alfonsi E, Restivo DA, Cosentino G et al (2017) Botulinum Toxin is effective in the management of neurogenic Dysphagia. Clinical-electrophysiological findings and Tips on Safety in different neurological disorders. Front Pharmacol 8:80. https:\/\/doi.org\/10.3389\/fphar.2017.00080","journal-title":"Front Pharmacol"},{"key":"2805_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.parkreldis.2018.11.003","volume":"62","author":"CA Artusi","year":"2019","unstructured":"Artusi CA, Bortolani S, Merola A et al (2019) Botulinum toxin for Pisa syndrome: an MRI-, ultrasound- and electromyography-guided pilot study. Parkinsonism Relat Disord 62:231\u2013235. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.11.003","journal-title":"Parkinsonism Relat Disord"},{"key":"2805_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1474-4422(05)70119-8","volume":"4","author":"R Ashour","year":"2005","unstructured":"Ashour R, Tintner R, Jankovic J (2005) Striatal deformities of the hand and foot in Parkinson\u2019s disease. Lancet Neurol 4:423\u2013431. https:\/\/doi.org\/10.1016\/S1474-4422(05)70119-8","journal-title":"Lancet Neurol"},{"key":"2805_CR6","first-page":"213","volume":"22","author":"H Bagheri","year":"1999","unstructured":"Bagheri H, Damase-Michel C, Lapeyre-Mestre M et al (1999) A study of salivary secretion in Parkinson\u2019s disease. Clin Neuropharmacol 22:213\u2013215","journal-title":"Clin Neuropharmacol"},{"key":"2805_CR7","doi-asserted-by":"publisher","first-page":"43588","DOI":"10.1038\/srep43588","volume":"7","author":"RM Benoit","year":"2017","unstructured":"Benoit RM, Sch\u00e4rer MA, Wieser MM et al (2017) Crystal structure of the BoNT\/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C. Sci Rep 7:43588. https:\/\/doi.org\/10.1038\/srep43588","journal-title":"Sci Rep"},{"key":"2805_CR8","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00005537-199810000-00003","volume":"108","author":"A Blitzer","year":"1998","unstructured":"Blitzer A, Brin MF, Stewart CF (1998) Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 108:1435\u20131441. https:\/\/doi.org\/10.1097\/00005537-199810000-00003","journal-title":"Laryngoscope"},{"key":"2805_CR9","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1002\/mds.21694","volume":"22","author":"L Bonanni","year":"2007","unstructured":"Bonanni L, Thomas A, Varanese S et al (2007) Botulinum toxin treatment of lateral axial dystonia in parkinsonism. Mov Disord 22:2097\u20132103. https:\/\/doi.org\/10.1002\/mds.21694","journal-title":"Mov Disord"},{"key":"2805_CR10","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1212\/WNL.56.11.1523","volume":"56","author":"MF Brin","year":"2001","unstructured":"Brin MF, Lyons KE, Doucette J et al (2001) A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 56:1523\u20131528. https:\/\/doi.org\/10.1212\/WNL.56.11.1523","journal-title":"Neurology"},{"key":"2805_CR11","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/toxins7061882","volume":"7","author":"G Brisinda","year":"2015","unstructured":"Brisinda G, Sivestrini N, Bianco G, Maria G (2015) Treatment of gastrointestinal sphincters spasms with Botulinum Toxin A. Toxins 7:1882\u20131916. https:\/\/doi.org\/10.3390\/toxins7061882","journal-title":"Toxins"},{"key":"2805_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1017\/cjn.2016.279","volume":"43","author":"VA Bruno","year":"2016","unstructured":"Bruno VA, Fox SH, Mancini D, Miyasaki JM (2016) Botulinum Toxin Use in Refractory Pain and other symptoms in parkinsonism. Can J Neurol Sci \/ J Canadien Des Sci Neurologiques 43:697\u2013702. https:\/\/doi.org\/10.1017\/cjn.2016.279","journal-title":"Can J Neurol Sci \/ J Canadien Des Sci Neurologiques"},{"key":"2805_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mds.23929","volume":"27","author":"R Chinnapongse","year":"2012","unstructured":"Chinnapongse R, Gullo K, Nemeth P et al (2012) Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson\u2019s disease: a prospective double-blind trial. Mov Disord 27:219\u2013226. https:\/\/doi.org\/10.1002\/mds.23929","journal-title":"Mov Disord"},{"key":"2805_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/toxins13010058","volume":"13","author":"S Choudhury","year":"2021","unstructured":"Choudhury S, Baker MR, Chatterjee S, Kumar H (2021) Botulinum Toxin: an update on pharmacology and newer products in Development. Toxins 13:58. https:\/\/doi.org\/10.3390\/toxins13010058","journal-title":"Toxins"},{"key":"2805_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/mds.22249","volume":"24","author":"C Colosimo","year":"2009","unstructured":"Colosimo C, Salvatori FM (2009) Injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord 24:316\u2013317. https:\/\/doi.org\/10.1002\/mds.22249","journal-title":"Mov Disord"},{"key":"2805_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/toxins16010009","volume":"16","author":"C Cutrona","year":"2023","unstructured":"Cutrona C, Marchet F, Costanzo M et al (2023) Exploring the Central Mechanisms of Botulinum Toxin in Parkinson\u2019s Disease: a systematic review from animal models to human evidence. Toxins 16:9. https:\/\/doi.org\/10.3390\/toxins16010009","journal-title":"Toxins"},{"key":"2805_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","volume":"61","author":"P Denys","year":"2012","unstructured":"Denys P, Le Normand L, Ghout I et al (2012) Efficacy and safety of low doses of OnabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a Multicentre, Double-Blind, randomised, placebo-controlled dose-ranging study. Eur Urol 61:520\u2013529. https:\/\/doi.org\/10.1016\/j.eururo.2011.10.028","journal-title":"Eur Urol"},{"key":"2805_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1474-4422(11)70067-9","volume":"10","author":"KM Doherty","year":"2011","unstructured":"Doherty KM, van de Warrenburg BP, Peralta MC et al (2011) Postural deformities in Parkinson\u2019s disease. Lancet Neurol 10:538\u2013549. https:\/\/doi.org\/10.1016\/S1474-4422(11)70067-9","journal-title":"Lancet Neurol"},{"key":"2805_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1590\/S0004-282X2005000100035","volume":"63","author":"D Dressler","year":"2005","unstructured":"Dressler D, Saberi FA, Barbosa ER (2005) Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 63:180\u2013185. https:\/\/doi.org\/10.1590\/S0004-282X2005000100035","journal-title":"Arq Neuropsiquiatr"},{"key":"2805_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.parkreldis.2015.03.027","volume":"21","author":"A Dupeyron","year":"2015","unstructured":"Dupeyron A, Viollet E, Coroian F et al (2015) Botulinum Toxin-A for treatment of Pisa syndrome: a new target muscle. Parkinsonism Relat Disord 21:669\u2013670. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.03.027","journal-title":"Parkinsonism Relat Disord"},{"key":"2805_CR21","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/mds.20003","volume":"19","author":"FJ Erbguth","year":"2004","unstructured":"Erbguth FJ (2004) Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord 19:S2\u2013S6. https:\/\/doi.org\/10.1002\/mds.20003","journal-title":"Mov Disord"},{"key":"2805_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00702-007-0728-2","volume":"115","author":"FJ Erbguth","year":"2007","unstructured":"Erbguth FJ (2007) From poison to remedy: the chequered history of botulinum toxin. J Neural Transm 115:559\u2013565. https:\/\/doi.org\/10.1007\/s00702-007-0728-2","journal-title":"J Neural Transm"},{"key":"2805_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/mds.23522","volume":"26","author":"AJ Espay","year":"2011","unstructured":"Espay AJ, Vaughan JE, Shukla R et al (2011) Botulinum toxin type A for levodopa-induced cervical dyskinesias in Parkinson\u2019s disease: unfavorable risk\u2010benefit ratio. Mov Disord 26:913\u2013914. https:\/\/doi.org\/10.1002\/mds.23522","journal-title":"Mov Disord"},{"key":"2805_CR24","doi-asserted-by":"publisher","first-page":"106242","DOI":"10.1016\/j.clineuro.2020.106242","volume":"198","author":"M Etoom","year":"2020","unstructured":"Etoom M, Alwardat M, Aburub AS et al (2020) Therapeutic interventions for Pisa syndrome in idiopathic Parkinson\u2019s disease. Scoping Syst Rev Clin Neurol Neurosurg 198:106242. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106242","journal-title":"Scoping Syst Rev Clin Neurol Neurosurg"},{"key":"2805_CR25","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/mds.22676","volume":"24","author":"UM Fietzek","year":"2009","unstructured":"Fietzek UM, Schroeteler FE, Ceballos-Baumann AO (2009) Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin. Mov Disord 24:2027\u20132028. https:\/\/doi.org\/10.1002\/mds.22676","journal-title":"Mov Disord"},{"key":"2805_CR26","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.juro.2011.04.071","volume":"186","author":"A Giannantoni","year":"2011","unstructured":"Giannantoni A, Conte A, Proietti S et al (2011) Botulinum Toxin type A in patients with Parkinson\u2019s disease and refractory overactive bladder. J Urol 186:960\u2013964. https:\/\/doi.org\/10.1016\/j.juro.2011.04.071","journal-title":"J Urol"},{"key":"2805_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jnnp.57.5.659","volume":"57","author":"N Giladi","year":"1994","unstructured":"Giladi N, Meer J, Honigman S (1994) The use of botulinum toxin to treat striatal toes. J Neurol Neurosurg Psychiatry 57:659\u2013659. https:\/\/doi.org\/10.1136\/jnnp.57.5.659","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2805_CR213","doi-asserted-by":"publisher","unstructured":"Giladi N, Gurevich T, Shabtai H, et al.(2001) The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J Neurol  248: 572\u2013576https:\/\/doi.org\/10.1007\/s004150170134","DOI":"10.1007\/s004150170134"},{"key":"2805_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.23473","volume":"26","author":"A Guidubaldi","year":"2011","unstructured":"Guidubaldi A, Fasano A, Ialongo T et al (2011) Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson\u2019s disease. Mov Disord 26:313\u2013319. https:\/\/doi.org\/10.1002\/mds.23473","journal-title":"Mov Disord"},{"key":"2805_CR29","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/mds.21396","volume":"22","author":"T Gurevich","year":"2007","unstructured":"Gurevich T, Peretz C, Moore O et al (2007) The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson\u2019s disease: a double blind placebo-controlled pilot study. Mov Disord 22:880\u2013883. https:\/\/doi.org\/10.1002\/mds.21396","journal-title":"Mov Disord"},{"key":"2805_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","volume":"67","author":"M Hallett","year":"2013","unstructured":"Hallett M, Albanese A, Dressler D et al (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 67:94\u2013114. https:\/\/doi.org\/10.1016\/j.toxicon.2012.12.004","journal-title":"Toxicon"},{"key":"2805_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/1756285614557475","volume":"8","author":"A Hellman","year":"2015","unstructured":"Hellman A, Torres-Russotto D (2015) Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Ther Adv Neurol Disord 8:82\u201391. https:\/\/doi.org\/10.1177\/1756285614557475","journal-title":"Ther Adv Neurol Disord"},{"key":"2805_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000117196","volume":"36","author":"JM Henderson","year":"1996","unstructured":"Henderson JM, Ghika JA, Van Melle G et al (1996) Botulinum Toxin A in non-dystonic tremors. Eur Neurol 36:29\u201335. https:\/\/doi.org\/10.1159\/000117196","journal-title":"Eur Neurol"},{"key":"2805_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2019.4565","volume":"77","author":"SH Isaacson","year":"2020","unstructured":"Isaacson SH, Ondo W, Jackson CE et al (2020) Safety and efficacy of RimabotulinumtoxinB for treatment of Sialorrhea in adults. JAMA Neurol 77:461. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4565","journal-title":"JAMA Neurol"},{"key":"2805_CR34","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.toxicon.2008.11.013","volume":"54","author":"J Jankovic","year":"2009","unstructured":"Jankovic J (2009) Disease-oriented approach to botulinum toxin use. Toxicon 54:614\u2013623. https:\/\/doi.org\/10.1016\/j.toxicon.2008.11.013","journal-title":"Toxicon"},{"key":"2805_CR35","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/WNL.41.8.1185","volume":"41","author":"J Jankovic","year":"1991","unstructured":"Jankovic J, Schwartz K (1991) Botulinum toxin treatment of tremors. Neurology 41:1185\u20131185. https:\/\/doi.org\/10.1212\/WNL.41.8.1185","journal-title":"Neurology"},{"key":"2805_CR36","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/mds.870110306","volume":"11","author":"J Jankovic","year":"1996","unstructured":"Jankovic J, Schwartz K, Clemence W et al (1996) A randomized, double-blind, placebo\u2010controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 11:250\u2013256. https:\/\/doi.org\/10.1002\/mds.870110306","journal-title":"Mov Disord"},{"key":"2805_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jns.2009.08.020","volume":"289","author":"WH Jost","year":"2010","unstructured":"Jost WH (2010) Gastrointestinal dysfunction in Parkinson\u2019s Disease. J Neurol Sci 289:69\u201373. https:\/\/doi.org\/10.1016\/j.jns.2009.08.020","journal-title":"J Neurol Sci"},{"key":"2805_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00702-012-0914-8","volume":"120","author":"WH Jost","year":"2013","unstructured":"Jost WH (2013) Urological problems in Parkinson\u2019s disease: clinical aspects. J Neural Transm 120:587\u2013591. https:\/\/doi.org\/10.1007\/s00702-012-0914-8","journal-title":"J Neural Transm"},{"key":"2805_CR42","unstructured":"Jost WH (2019) Atlas of Botulinum Toxin Injection (3rd edition). Quintessence Publishing, London"},{"key":"2805_CR40","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1080\/14656566.2019.1639672","volume":"20","author":"WH Jost","year":"2019","unstructured":"Jost WH, Buhmann C (2019) The challenge of pain in the pharmacological management of Parkinson\u2019s disease. Expert Opin Pharmacother 20:1847\u20131854. https:\/\/doi.org\/10.1080\/14656566.2019.1639672","journal-title":"Expert Opin Pharmacother"},{"key":"2805_CR44","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/003655299750026146","volume":"34","author":"WH Jost","year":"1999","unstructured":"Jost WH, Schrank B, Herold A et al (1999) Functional outlet obstruction: Anismus, spastic pelvic floor syndrome, and Dyscoordination of the Voluntary Sphincter muscles: definition, diagnosis, and treatment from the neurologic point of View. Scand J Gastroenterol 34:449\u2013453. https:\/\/doi.org\/10.1080\/003655299750026146","journal-title":"Scand J Gastroenterol"},{"key":"2805_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40120-019-00155-6","volume":"8","author":"WH Jost","year":"2019","unstructured":"Jost WH, B\u00e4umer T, Laskawi R et al (2019a) Therapy of Sialorrhea with Botulinum Neurotoxin. Neurol Ther 8:273\u2013288. https:\/\/doi.org\/10.1007\/s40120-019-00155-6","journal-title":"Neurol Ther"},{"key":"2805_CR41","doi-asserted-by":"publisher","unstructured":"Jost WH, Friedman A, Michel O et al (2019b) SIAXI: placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology 92: e1982-e1991. https:\/\/doi.org\/10.1212\/WNL.0000000000007368","DOI":"10.1212\/WNL.0000000000007368"},{"key":"2805_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.parkreldis.2019.11.024","volume":"70","author":"WH Jost","year":"2020","unstructured":"Jost WH, Friedman A, Michel O et al (2020) Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks. Parkinsonism Relat Disord 70:23\u201330. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.11.024","journal-title":"Parkinsonism Relat Disord"},{"key":"2805_CR45","first-page":"1","volume":"3","author":"J Kerner","year":"1817","unstructured":"Kerner J (1817) Vergiftung durch verdorbene W\u00fcrste. T\u00fcbinger Bl\u00e4tter f\u00fcr Naturwissenschaften Und Arzneykunde 3:1\u201325","journal-title":"T\u00fcbinger Bl\u00e4tter f\u00fcr Naturwissenschaften Und Arzneykunde"},{"issue":"1","key":"2805_CR46","doi-asserted-by":"publisher","first-page":"e33486","DOI":"10.7759\/cureus.33486","volume":"15","author":"HA Khan","year":"2023","unstructured":"Khan HA (2023) Use of Botulinum Toxin in Spasmodic Dysphonia: a review of recent studies. Cureus 15(1):e33486. https:\/\/doi.org\/10.7759\/cureus.33486","journal-title":"Cureus"},{"key":"2805_CR47","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/mds.20793","volume":"21","author":"G Lagalla","year":"2006","unstructured":"Lagalla G, Millevolte M, Capecci M et al (2006) Botulinum toxin type A for drooling in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 21:704\u2013707. https:\/\/doi.org\/10.1002\/mds.20793","journal-title":"Mov Disord"},{"key":"2805_CR48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","volume":"256","author":"G Lagalla","year":"2009","unstructured":"Lagalla G, Millevolte M, Capecci M et al (2009) Long-lasting benefits of botulinum toxin type B in Parkinson\u2019s disease-related drooling. J Neurol 256:563\u2013567. https:\/\/doi.org\/10.1007\/s00415-009-0085-1","journal-title":"J Neurol"},{"key":"2805_CR49","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1212\/WNL.35.3.423","volume":"35","author":"FE Lepore","year":"1985","unstructured":"Lepore FE, Duvoisin RC (1985) Apraxia of eyelid opening. Neurology 35:423\u2013423. https:\/\/doi.org\/10.1212\/WNL.35.3.423","journal-title":"Neurology"},{"key":"2805_CR50","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1212\/WNL.61.9.1279","volume":"61","author":"A Lipp","year":"2003","unstructured":"Lipp A, Trottenberg T, Schink T et al (2003) A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61:1279\u20131281. https:\/\/doi.org\/10.1212\/WNL.61.9.1279","journal-title":"Neurology"},{"key":"2805_CR51","first-page":"41","volume":"2","author":"S Lubik","year":"2002","unstructured":"Lubik S, Jost W, B\u00f6nhof J (2002) Ultraschallgest\u00fctzte Botulinumtoxin- Injektionen in den M. psoas. ZNS Schmerz 2:41\u201344","journal-title":"ZNS Schmerz"},{"key":"2805_CR52","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.otohns.2008.05.624","volume":"139","author":"CL Ludlow","year":"2008","unstructured":"Ludlow CL, Adler CH, Berke GS et al (2008) Research priorities in spasmodic dysphonia. Otolaryngology\u2013Head Neck Surg 139:495\u2013505. https:\/\/doi.org\/10.1016\/j.otohns.2008.05.624","journal-title":"Otolaryngology\u2013Head Neck Surg"},{"key":"2805_CR53","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/mds.10420","volume":"18","author":"F Mancini","year":"2003","unstructured":"Mancini F, Zangaglia R, Cristina S et al (2003) Double-blind, placebo\u2010controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18:685\u2013688. https:\/\/doi.org\/10.1002\/mds.10420","journal-title":"Mov Disord"},{"key":"2805_CR54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.5334\/tohm.186","volume":"4","author":"D Martinez-Ramirez","year":"2014","unstructured":"Martinez-Ramirez D, Giugni JC, Hastings E et al (2014) Comparable Botulinum Toxin outcomes between primary and secondary blepharospasm: a retrospective analysis. Tremor Other Hyperkinetic Movements 4:286. https:\/\/doi.org\/10.5334\/tohm.186","journal-title":"Tremor Other Hyperkinetic Movements"},{"key":"2805_CR55","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.3390\/toxins7093758","volume":"7","author":"M Mazlan","year":"2015","unstructured":"Mazlan M, Rajasegaran S, Engkasan J et al (2015) A double-blind randomized controlled trial investigating the most efficacious dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian adults with neurological diseases. Toxins 7:3758\u20133770. https:\/\/doi.org\/10.3390\/toxins7093758","journal-title":"Toxins"},{"key":"2805_CR56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/toxins13030226","volume":"13","author":"SD Mitchell","year":"2021","unstructured":"Mitchell SD, Sidiropoulos C (2021) Therapeutic applications of Botulinum Neurotoxin for autonomic symptoms in Parkinson\u2019s Disease. Updated Rev Toxins 13:226. https:\/\/doi.org\/10.3390\/toxins13030226","journal-title":"Updated Rev Toxins"},{"key":"2805_CR57","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.mayocp.2017.06.010","volume":"92","author":"SO Mittal","year":"2017","unstructured":"Mittal SO, Machado D, Richardson D et al (2017) Botulinum Toxin in Parkinson Disease Tremor. Mayo Clin Proc 92:1359\u20131367. https:\/\/doi.org\/10.1016\/j.mayocp.2017.06.010","journal-title":"Mayo Clin Proc"},{"key":"2805_CR58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.parkreldis.2018.06.019","volume":"56","author":"SO Mittal","year":"2018","unstructured":"Mittal SO, Machado D, Richardson D et al (2018) Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach. Parkinsonism Relat Disord 56:65\u201369. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.06.019","journal-title":"Parkinsonism Relat Disord"},{"key":"2805_CR59","doi-asserted-by":"publisher","first-page":"107587","DOI":"10.1016\/j.toxicon.2023.107587","volume":"238","author":"P Ni","year":"2024","unstructured":"Ni P, Xu Y, Wang L et al (2024) Evaluation of therapeutic benefits of botulinum toxin for foot dystonia associated with Parkinson\u2019s disease. Toxicon 238:107587. https:\/\/doi.org\/10.1016\/j.toxicon.2023.107587","journal-title":"Toxicon"},{"key":"2805_CR60","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/lary.21395","volume":"121","author":"D Novakovic","year":"2011","unstructured":"Novakovic D, Waters HH, D\u2019Elia JB, Blitzer A (2011) Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. Laryngoscope 121:606\u2013612. https:\/\/doi.org\/10.1002\/lary.21395","journal-title":"Laryngoscope"},{"key":"2805_CR61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","volume":"62","author":"WG Ondo","year":"2004","unstructured":"Ondo WG, Hunter C, Moore W (2004) A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson\u2019s disease. Neurology 62:37\u201340. https:\/\/doi.org\/10.1212\/01.WNL.0000101713.81253.4C","journal-title":"Neurology"},{"key":"2805_CR62","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/0970-1591.109975","volume":"29","author":"B Orasanu","year":"2013","unstructured":"Orasanu B, Mahajan S (2013) The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol 29:2. https:\/\/doi.org\/10.4103\/0970-1591.109975","journal-title":"Indian J Urol"},{"key":"2805_CR63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.toxicon.2015.08.014","volume":"107","author":"M Petracca","year":"2015","unstructured":"Petracca M, Guidubaldi A, Ricciardi L et al (2015) Botulinum Toxin A and B in sialorrhea: long-term data and literature overview. Toxicon 107:129\u2013140. https:\/\/doi.org\/10.1016\/j.toxicon.2015.08.014","journal-title":"Toxicon"},{"key":"2805_CR64","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1124\/pr.116.012658","volume":"69","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini M, Rossetto O, Eleopra R, Montecucco C (2017) Botulinum neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev 69:200\u2013235. https:\/\/doi.org\/10.1124\/pr.116.012658","journal-title":"Pharmacol Rev"},{"key":"2805_CR65","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archneur.1996.00550070055012","volume":"53","author":"SL Pullman","year":"1996","unstructured":"Pullman SL (1996) Approach to the treatment of Limb disorders with Botulinum Toxin A. Arch Neurol 53:617. https:\/\/doi.org\/10.1001\/archneur.1996.00550070055012","journal-title":"Arch Neurol"},{"key":"2805_CR66","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1017\/S031716710001489X","volume":"40","author":"F Rahimi","year":"2013","unstructured":"Rahimi F, Bee C, Debicki D et al (2013) Effectiveness of BoNT A in Parkinson\u2019s Disease Upper Limb Tremor Management. Can J Neurol Sci \/ J Canadien Des Sci Neurologiques 40:663\u2013669. https:\/\/doi.org\/10.1017\/S031716710001489X","journal-title":"Can J Neurol Sci \/ J Canadien Des Sci Neurologiques"},{"key":"2805_CR67","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1056\/NEJM200204113461517","volume":"346","author":"DA Restivo","year":"2002","unstructured":"Restivo DA, Palmeri A, Marchese-Ragona R (2002) Botulinum Toxin for Cricopharyngeal Dysfunction in Parkinson\u2019s Disease. N Engl J Med 346:1174\u20131175. https:\/\/doi.org\/10.1056\/NEJM200204113461517","journal-title":"N Engl J Med"},{"key":"2805_CR68","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00702-019-02025-9","volume":"126","author":"P Riederer","year":"2019","unstructured":"Riederer P, Berg D, Casadei N et al (2019) \u03b1-Synuclein in Parkinson\u2019s disease: causal or bystander? J Neural Transm 126:815\u2013840. https:\/\/doi.org\/10.1007\/s00702-019-02025-9","journal-title":"J Neural Transm"},{"key":"2805_CR70","doi-asserted-by":"publisher","first-page":"e0178670","DOI":"10.1371\/journal.pone.0178670","volume":"12","author":"O Samotus","year":"2017","unstructured":"Samotus O, Lee J, Jog M (2017) Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS ONE 12:e0178670. https:\/\/doi.org\/10.1371\/journal.pone.0178670","journal-title":"PLoS ONE"},{"key":"2805_CR69","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/toxins11020125","volume":"11","author":"O Samotus","year":"2019","unstructured":"Samotus O, Lee J, Jog M (2019) Personalized bilateral Upper Limb essential tremor therapy with Botulinum Toxin using kinematics. Toxins 11:125. https:\/\/doi.org\/10.3390\/toxins11020125","journal-title":"Toxins"},{"key":"2805_CR71","doi-asserted-by":"publisher","first-page":"175628642095408","DOI":"10.1177\/1756286420954083","volume":"13","author":"O Samotus","year":"2020","unstructured":"Samotus O, Lee J, Jog M (2020) Standardized algorithm for muscle selection and dosing of botulinum toxin for Parkinson tremor using kinematic analysis. Ther Adv Neurol Disord 13:175628642095408. https:\/\/doi.org\/10.1177\/1756286420954083","journal-title":"Ther Adv Neurol Disord"},{"key":"2805_CR72","doi-asserted-by":"publisher","unstructured":"Santos-Garc\u00eda D, de Deus T, Cores C et al (2024) Levodopa\u2010Induced dyskinesias are frequent and Impact Quality of Life in Parkinson\u2019s Disease: a 5\u2010Year Follow\u2010Up study. https:\/\/doi.org\/10.1002\/mdc3.14056. Mov Disord Clin Pract","DOI":"10.1002\/mdc3.14056"},{"key":"2805_CR73","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1002\/mds.21006","volume":"21","author":"P Schestatsky","year":"2006","unstructured":"Schestatsky P, Valls-Sol\u00e9 J, Ehlers JA et al (2006) Hyperhidrosis in Parkinson\u2019s disease. Mov Disord 21:1744\u20131748. https:\/\/doi.org\/10.1002\/mds.21006","journal-title":"Mov Disord"},{"key":"2805_CR74","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/mds.10586","volume":"18","author":"L Swinn","year":"2003","unstructured":"Swinn L, Schrag A, Viswanathan R et al (2003) Sweating dysfunction in Parkinson\u2019s disease. Mov Disord 18:1459\u20131463. https:\/\/doi.org\/10.1002\/mds.10586","journal-title":"Mov Disord"},{"key":"2805_CR75","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.parkreldis.2014.07.015","volume":"20","author":"C Tassorelli","year":"2014","unstructured":"Tassorelli C, De Icco R, Alfonsi E et al (2014) Botulinum toxin type a potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord 20:1140\u20131144. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.07.015","journal-title":"Parkinsonism Relat Disord"},{"key":"2805_CR76","doi-asserted-by":"publisher","first-page":"379","DOI":"10.5603\/PJNNS.a2022.0024","volume":"56","author":"MF Thiel","year":"2022","unstructured":"Thiel MF, Altmann CF, Jost WH (2022) Cervical dystonia in Parkinson\u2019s Disease: frequency of occurrence and subtypes. Neurol Neurochir Pol 56:379\u2013380. https:\/\/doi.org\/10.5603\/PJNNS.a2022.0024","journal-title":"Neurol Neurochir Pol"},{"key":"2805_CR77","doi-asserted-by":"publisher","first-page":"vii7","DOI":"10.1007\/s00415-006-7003-6","volume":"253","author":"E Tolosa","year":"2006","unstructured":"Tolosa E, Compta Y (2006) Dystonia in Parkinson\u2019s disease. J Neurol 253:vii7\u2013vii13. https:\/\/doi.org\/10.1007\/s00415-006-7003-6","journal-title":"J Neurol"},{"key":"2805_CR78","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.parkreldis.2017.08.020","volume":"44","author":"G Triadafilopoulos","year":"2017","unstructured":"Triadafilopoulos G, Gandhy R, Barlow C (2017) Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson\u2019s disease. Parkinsonism Relat Disord 44:33\u201337. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.08.020","journal-title":"Parkinsonism Relat Disord"},{"key":"2805_CR79","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/mds.870090604","volume":"9","author":"RM Trosch","year":"1994","unstructured":"Trosch RM, Pullman SL (1994) Botulinum toxin a injections for the treatment of hand tremors. Mov Disord 9:601\u2013609. https:\/\/doi.org\/10.1002\/mds.870090604","journal-title":"Mov Disord"},{"key":"2805_CR80","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5603\/PJNNS.a2020.0021","volume":"54","author":"M Ty\u015blerowicz","year":"2020","unstructured":"Ty\u015blerowicz M, Kiedrzy\u0144ska W, Adamkiewicz B et al (2020) Cervical dystonia \u2014 improving the effectiveness of botulinum toxin therapy. Neurol Neurochir Pol 54:232\u2013242. https:\/\/doi.org\/10.5603\/PJNNS.a2020.0021","journal-title":"Neurol Neurochir Pol"},{"key":"2805_CR81","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/mds.21967","volume":"23","author":"R von Coelln","year":"2008","unstructured":"von Coelln R, Raible A, Gasser T, Asmus F (2008) Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord 23:889\u2013892. https:\/\/doi.org\/10.1002\/mds.21967","journal-title":"Mov Disord"},{"key":"2805_CR82","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/mds.23469","volume":"26","author":"MM Wickremaratchi","year":"2011","unstructured":"Wickremaratchi MM, Knipe MDW, Sastry BSD et al (2011) The motor phenotype of Parkinson\u2019s disease in relation to age at onset. Mov Disord 26:457\u2013463. https:\/\/doi.org\/10.1002\/mds.23469","journal-title":"Mov Disord"},{"key":"2805_CR83","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/01.wnl.0000172930.63669.c8","volume":"65","author":"M Wieler","year":"2005","unstructured":"Wieler M, Camicioli R, Jones CA, Wayne Martin WR (2005) Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology 65:626\u2013628. https:\/\/doi.org\/10.1212\/01.wnl.0000172930.63669.c8","journal-title":"Neurology"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-024-02805-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T14:04:36Z","timestamp":1729778676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-024-02805-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":84,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2805"],"URL":"https:\/\/doi.org\/10.1007\/s00702-024-02805-y","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}